key: cord-0901967-v4k5vljg
authors: Quadeer, Ahmed Abdul; Ahmed, Syed Faraz; McKay, Matthew R.
title: Landscape of epitopes targeted by T cells in 852 convalescent COVID-19 patients: Meta-analysis, immunoprevalence and web platform
date: 2021-05-21
journal: Cell Rep Med
DOI: 10.1016/j.xcrm.2021.100312
sha: 61533024852141b348cdff7dcfc115ba8c8a63bd
doc_id: 901967
cord_uid: v4k5vljg

Knowledge of the epitopes of SARS-CoV-2 targeted by T cells in convalescent patients is important for understanding T cell immunity against COVID-19. This information can aid the development and assessment of COVID-19 vaccines, and inform novel diagnostic technologies. Here we provide a unified description and meta-analysis of SARS-CoV-2 T cell epitopes compiled from 18 studies of cohorts of convalescent COVID-19 patients (852 patients in total). Our analysis demonstrates the broad diversity of T cell epitopes that have been recorded for SARS-CoV-2. A large majority are seemingly unaffected by current variants of concern. We identify a set of 20 immunoprevalent epitopes that induced T cell responses in multiple cohorts and in a large fraction of tested patients. The landscape of SARS-CoV-2 T cell epitopes that we describe can help guide immunological studies, including those related to vaccines and diagnostics. A web-based platform has been developed to help complement these efforts.

1 Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative agent of COVID-19, has led to a 2 global public health crisis. Development of COVID-19 vaccines and diagnostic tests are aided by an understanding 3 of the natural protective immune responses against SARS-CoV-2. This includes both humoral and cellular immunity, 4 mediated by antibodies and T cells respectively. Significant COVID-19 research has focused on understanding 5 antibody responses [1] [2] [3] ; though, studies informing the role of T cells have also started to emerge. 6 7 Initial results suggest the potential key role that T cells may play in protecting against COVID-19 4, 5 . Studies of 8 convalescent COVID-19 patients have detected SARS-CoV-2-specific T cells nine months post infection 6 , giving 9

promising signs for the potential of T cells to provide lasting immunity. Longevity may be a concern for antibody 10 responses, which have been reported to decline within just a few months post infection [7] [8] [9] . Consistent observations 11 have also been reported for the most closely related human coronavirus, SARS-CoV, for which T cells were shown 12 to persist up to 17 years post infection 10 , whereas antibody responses waned after a few years 11 . 13

14 Characterizing SARS-CoV-2 T cell epitopes, as well as their human leukocyte antigen (HLA) association, is 15 important for multiple reasons. It informs of the expected SARS-CoV-2 natural or vaccine-induced T cell responses 16 in a population of specific ethnicity or a specific geographical region, which is tied to the composition of HLA alleles 17 prevalent in that population. It can help in assessing the T cell responses that may be induced by COVID- 19 18 vaccines (which currently mainly focus on the spike (S) protein 12 ), while providing possible directions for boosting the 19 T cell response by including specific immunodominant epitopes. It can guide vaccine assessment studies in probing 20 whether a vaccine induces T cell responses similar to those commonly generated during natural infection. It can also 21 aid in monitoring potential viral escape from T cell responses via genetic mutations, and can facilitate the 22 development of T-cell-based diagnostics for distinguishing convalescent from unexposed individuals. T-cell-based 23 diagnostics may have advantages over serological assays given the uncertainties related to the appearance and 24 persistence of SARS-CoV-2-specific antibody responses in infected patients [7] [8] [9] 13 . 25 26 Here, we present a unified account of the current knowledge (as of 20 April 2021) of SARS-CoV-2 T cell epitopes 27 associated with convalescent COVID-19 patients. We collate and analyse data of T cell epitopes that have been 28 identified experimentally in independent studies of blood samples from different patient cohorts. This data is 29 compiled from 18 studies (15 published, 3 preprints) of T cell responses in a total of 852 convalescent COVID-19 30 patients (Table 1 ). Our analysis highlights the different characteristics of epitopes reported for SARS-CoV-2, and 31 identifies a specific set of epitopes that appear to induce T cell responses in multiple cohorts and in a large fraction 32 of tested patients. This information of SARS-CoV-2 T cell epitopes can provide directions for future immunological 1 studies. We report a web dashboard that we have developed to support these on-going scientific efforts. 2 3 4 In the considered 18 studies, the set of convalescent patients collectively cover a population across four continents 5 and are well distributed in age, gender, disease severity, and blood collection time, within and across studies ( Table  6 1). Half of the studies have characterized T cell responses against the whole proteome, while the others have 7 focused on responses mounted against subsets of SARS-CoV-2 proteins, typically involving the S and nucleocapsid 8 (N) proteins. In the majority of cases, the T cell response was measured in blood samples of patients against a set of 9 peptides predicted by bioinformatic tools or earlier bioinformatic-based analyses [14] [15] [16] (reviewed in ref. 17 ), while a few 10 studies employed overlapping peptide pools spanning the SARS-CoV-2 proteome. All 18 studies reported optimal 11 epitopes along with cognate HLA information. Of these, ten studies (no. 1-10 in Table 1 ) determined HLA restrictions 12 of the reported epitopes experimentally using multimer qualitative binding. Of the remaining eight studies, one study 13 (no. 11 in Table 1 ) employed mono-allelic cell line assays to identify specific HLA-restricted epitopes, while others 14 (no. 12-18 in Table 1 ) inferred HLA restrictions using standard functional assays (such as activation induced marker 15 (AIM) or ICS/ELISPOT IFN-γ release) and HLA haplotype information of patients. While the latter set of studies 16 involved some predictive element in deconvolving from the patient haplotype the HLA allele responsible for the 17 observed response, the reported HLA associations were supported by either testing HLA binding assays or the use 18 of accurate peptide-HLA binding prediction methods. 19 20 A total of 711 unique T cell epitopes with the information of cognate HLA allele have been reported in the 18 21 immunological studies considered (see Methods for details). Of these, 635 are CD8 + (HLA class I restricted) and 76 22 are CD4 + (HLA class II restricted) ( Figure 1A ). The set of epitopes cover each protein from the canonical reading 23 frames of SARS-CoV-2, except ORF7b and ORF10. The largest number of epitopes fall within S and ORF1a-the 24 most exposed protein and the longest SARS-CoV-2 ORF respectively. These epitopes broadly cover almost the 25 entire S protein including the receptor-binding domain, while the majority of epitopes in ORF1a lie within the nsp3 26 (PL2-PROPapain-like proteinase) and nsp4 proteins (Supplementary File S1). These nsp3 and nsp4 proteins 27 together participate in the assembly of virally-induced cytoplasmic double-membrane vesicles that are necessary for 28 viral replication 18 . 29 30 All identified epitopes have high genetic conservation (>0.9) among the ~860,000 SARS-CoV-2 sequences (as of 20 305 NVLFSTVFPPTSFGP 319 and 309 STVFPPTSF 317 , in ORF1b) have a very low conservation (~0.02), since they 1 encompass mutations (S:D614G and ORF1b:P314L; underlined) that are now dominant globally, with the former 2 mutation reported to have increased virus infectivity and transmission [19] [20] [21] . Two-thirds of the 24 epitopes (16/24) with 3 low genetic conservation (<0.9) belong to S. These make up ~8% (16/208) of all unique T cell epitopes derived from 4 S; four-fold higher than the fraction of epitopes with low conservation derived from all other proteins (~2%, 8/503). 5

This can be of interest in the context of T cell responses against current COVID-19 vaccines that focus largely on the 6 S protein, assuming that the T cell epitopes targeted in response to vaccination are similar to those seen in the 7 convalescent patients. While limited data is currently available about epitope-specific T cell responses following 8 vaccination, this assumption is partially supported by a study of eight S-derived epitopes reported to elicit T cell 9 responses in vaccinated persons 22 , for which we observe seven of them to be targeted in convalescent patients 10 (Supplementary File 1). Of the 16 S-derived T cell epitopes with low genetic conservation (<0.9), all but one 11 encompass sites harbouring mutations that define the variants of concern 23,24 (VOC) (Supplementary proteins is, at least in part, likely to be driven by escape from neutralizing antibodies 25 . Despite the potential of S-16 derived epitopes to escape T cells elicited to target the non-mutated epitopes (by either natural infection or 17 vaccination), responses against the significant majority of S-derived epitopes we study are not expected to be 18 affected by VOC ( Figure 1B ). Moreover, at the level of HLA alleles, for each of the 36 HLA alleles associated with S-19 derived epitopes, each of them is associated with at least one conserved (>0.9) S-derived epitope (Supplementary 20

File 1). Collectively, the observed heterogeneity of T cell responses against SARS-CoV-2 provides little evidence to 21 suggest that the observed genetic variation in the S protein may significantly affect T cell immunity, in line with a 22 recent report 26 . Escape from T cell pressure may become an important evolutionary factor once strong and diverse 23 selective pressures are imposed by widespread vaccination, and this requires close monitoring. 24 25 The overall set of reported epitopes have been associated to 52 HLA class I and II alleles ( Figure 1C ). Most HLA 26 alleles are associated with multiple epitopes, with 21 alleles each having an association with 14 epitopes or more. 27

The same epitope may be presented by multiple HLA alleles, as evidenced by studies of the related SARS-CoV 27 as 28 well as other viruses 28 . However, for the majority of SARS-CoV-2 epitopes, only a single associated HLA allele has 29 been reported so far ( Figure 1D ). This appears due, in part, to the limited number of convalescent COVID-19 30 patients that have been studied (Table 1 ). The limited number of associated HLA alleles translates to a median alleles associated with the identified SARS-CoV-2 epitopes is required for providing a more accurate indication of 1 their individual population coverage. An expanded list of likely HLA associations may be predicted for some of the 2 reported epitopes by using prior knowledge of genetically-matched experimentally-determined T cell epitopes of 3 SARS-CoV and their associated HLA alleles (for details, see Supplementary File S1 and Supplementary Figure S1 ). 4

These predictions, once confirmed, would provide an increase in the median population coverage of the selected 5 SARS-CoV-2 epitopes from 16.8% to 40%, with a few epitopes having around 60% coverage (Supplementary . This is because responses against each epitope-HLA pair were recorded in more than half of the 18 tested convalescent patients collectively across multiple studies, despite differences in characteristics of donor 19 cohorts (age, gender, geographical location, disease severity), blood collection time, and methodology used for 20 determining the epitopes (initial peptide selection procedure, T cell assay) (Table 1) . 21

All of the 20 identified immunoprevalent epitopes have high genetic conservation (>0.9) ( Figure 2B ), and none of 23 them encompass mutations associated with the current VOC. Interestingly, 35% of the immunoprevalent epitope-24 HLA pairs (n=20) had an identical match to experimentally-determined SARS-CoV epitope-HLA pairs ( Figure 2B ). 25

This fraction of matched epitope-HLA pairs is over three times higher than that (11%) in the complete set of SARS-26

CoV-2 epitope-HLA pairs (P<10 -3 , Fisher's exact test), suggesting that many of the immunoprevalent T cell epitopes 27 of SARS-CoV-2 are also cross-reactive to SARS-CoV. Of the 20 identified immunoprevalent epitope-HLA pairs, six 28 each belonged to N and ORF1a, four to S, three to ORF3a and one to M ( Figure 2B ). This indicates that ~80% of the 29 immunoprevalent epitopes lie in proteins other than S, suggesting that vaccine candidates targeting these proteins 30 may have benefits in terms of T cell immunity. Of the identified immunoprevalent epitopes, five epitopes (HLA-207 FTSDYYQLY 215 in ORF3a and 1637 TTDPSFLGRY 1646 in ORF1a, and HLA-A*24:02-restricted 1208 QYIKWPWYI 1216 1 in S) appeared highly immunoprevalent, eliciting T cell responses in more than ~60% of the tested convalescent 2 COVID-19 patients in four immunological studies or more. Collectively, around 71% of the global population is 3 estimated to carry the associated HLA alleles, and hence may generate a T cell response against at least one of 4 these five epitopes. Two of these highly immunoprevalent epitopes ( 105 SPRWYFYYL 113 in N and 269 YLQPRTFLL 277 in 5 S) are attracting considerable attention, and detailed analysis of T cell responses against them have been 6 reported 33-35

The SARS-CoV-2 T cell epitope data that we compile and report here has been integrated into a web-based 9 dashboard 36 ( Figure 3 ). This dashboard provides exportable data tables listing the SARS-CoV-2 epitopes, and 10 graphical displays to summarize different characteristics of the epitopes, including aggregate information as well as 11 specific details of the individual epitopes. We plan to update the dashboard with new experimental information as it 12 becomes available, with the goal of aiding further research in understanding T cell responses against SARS-CoV-2, 13 and in guiding studies related to COVID-19 vaccines and diagnostics. While we focused the current study on SARS-14

CoV-2-specific T cell responses recorded in convalescent patients, knowledge of T cell epitopes targeted in animal 15 studies 37,38 is also informative. These may inform potential immune targets in COVID-19-infected individuals, and can 16 help in guiding further immunological experiments that seek to probe T cell responses that arise due to natural 17 infection, or those elicited by vaccination. The SARS-CoV-2 epitopes reported to be targeted in animal models have 18 also been incorporated into the web dashboard. 19 20 Overall, the data that we have described based on recent experimental studies demonstrates an impressive and 21 diverse list of SARS-CoV-2 T cell epitopes targeted by convalescent COVID-19 patients. Subsets of these epitopes 22 exhibit desirable properties, including high genetic conservation and high response frequency across multiple 23 cohorts, and they appear to have the potential to collectively induce a T cell response in a large fraction of the 24 population. Current knowledge of the landscape of T cell epitopes for SARS-CoV-2 is still evolving however, and 25 further studies of different cohorts of convalescent patients, encompassing a broad diversity of HLA profiles, are 26 required to provide a more comprehensive understanding. Moreover, further systematic studies are required to 27 ascertain possible correlates between the responses against T cell epitopes and disease protection. The knowledge 28 of SARS-CoV-2 T cell epitopes could play an important role in contributing to the fight against COVID-19 by guiding 29 diverse applications and novel technologies, including the development, assessment and monitoring of vaccines, 30 and the development of improved diagnostic assays.

Limitations of the study 1 There are multiple limitations of our study. Our analysis is unable to make associations between epitope-specific T 2 cell responses and levels of disease severity, nor can it capture differences between T cell responses according to 3 age or gender. The majority of the immunological studies that we investigate do not report epitope-specific T cell 4 responses at such level of detail, and hence, such analysis could not be performed. In terms of the HLA associations 5 of the reported SARS-CoV-2 epitopes, our study predicted additional associations based on homology with 6 experimental T cell epitopes of SARS-CoV and their associated HLA alleles (Supplementary File S1). These 7 additional HLA associations, while promising, still need to be confirmed for SARS-CoV-2 by further immunological 8 studies. Moreover, our analysis mainly involved CD8 + T cell epitopes. This was due to the limited number of CD4 + T 9 cell epitopes that have been reported so far with a unique HLA allele association. Further experimental studies are 10 needed to precisely identify CD4 + T cell epitopes with distinct HLA alleles. This would help to determine potential 11 immunoprevalent CD4 + epitopes in the global population, similar to those reported for CD8 + T cells in this work, and 12 would contribute to providing a more comprehensive understanding of the relationship between T cell responses and 13 convalescence for COVID-19. Table S3 T cell epitopes from convalescent COVID-19 patients: Nguyen et al. Nguyen et al. 33 Figure 3C Response frequencies of SARS-CoV-2 T cell epitopes This paper; Mendeley data File S1; http://dx.doi.org/10.17632/ fwn3kbbh6y.1 Genetic conservation of SARS-CoV-2 T cell epitopes among SARS-CoV-2 sequences (as of 20 April 2021) 

We compiled data from 20 immunological studies that reported SARS-CoV-2 epitopes targeted by T cells in 16 convalescent COVID-19 patients. Two studies (Refs. 7, 10 ) reported responses against synthetic peptide pool libraries 17 using functional or molecular assays, and identified long immunogenic peptides. As complete information of epitopes 18 was not available in these studies, we focused on the remaining 18 studies that provided optimal epitopes along with 19 their HLA restriction (Table 1 ). All statistics related to the patients that participated in each of these 18 studies (age, 20 gender, geographical location, disease severity, blood collection time) are summarized in Table 1 . Across the 21 considered 18 studies, the total number of convalescent COVID-19 patients was 852. A total of 1,209 epitopes were 22 obtained from these immunological studies (Table 1) . Removing the epitopes with no HLA allele information and 23 those for which the number of tested and responded patients was not reported at a distinct epitope-HLA level 24 resulted in a total of 812 unique epitopes (711 unique epitope-HLA pairs; listed in Supplementary File S1). The conservation of each SARS-CoV-2 T cell epitope was calculated as the fraction of SARS-CoV-2 sequences that 4 encompassed the precise epitope sequence. The coverage of SARS-CoV-2 T cell epitopes at any position of a 5 protein was calculated by counting the number of epitopes that included that position. 6 7 Response frequency (RF) 8 RF score 29 was used to quantify the immunodominance of the SARS-CoV-2 epitopes reported to be recognized by T 9 cells in convalescent COVID-19 patients. The RF score of an epitope is defined as follows: 10

where is the number of subjects responding to the epitope in study , is the number of subjects tested for a 11 response against the epitope in study , and S is the total number of studies. An RF score calculated using a large 12 number of tested subjects would be more reliable than one calculated using relatively few subjects. To account for 13 this, we computed the 95% confidence interval for the RF score of each epitope using the binomial cumulative 14 distribution function 29 . In Figure 2 , we defined the confidence in RF value of an epitope as the inverse of the length of 15 the corresponding 95% confidence interval. That is, values of RF with a smaller 95% confidence interval have higher 16 confidence, and vice versa. 

Connecting clusters of COVID-19: An epidemiological and serological 16 investigation

Dissecting antibody-mediated protection against SARS-CoV-2

Neutralizing antibody responses to SARS-CoV-2 in a COVID-19 recovered patient cohort and their 21 implications. medRxiv, 2020.03.30

Antibody profiles in mild and severe cases of COVID-19

Preliminary identification of potential vaccine targets 20 for the COVID-19 coronavirus (SARS-CoV-2) based on SARS-CoV immunological studies

Identification and validation of 174 COVID-19 vaccine candidate epitopes reveals low performance of 26 common epitope prediction tools

In silico T cell epitope identification for 28 SARS-CoV-2: Progress and perspectives

A web-based dashboard for reporting epitopes 12 targeted by T cells in convalescent COVID-19 patients

SARS-CoV-2 mRNA vaccine design enabled by 15 prototype pathogen preparedness

Immunogenicity of a DNA vaccine candidate for COVID-19

SARS-CoV-2 genome-wide T cell epitope mapping reveals immunodominance and 21 substantial CD8 + T cell activation in COVID-19 patients

SARS-CoV-2-specific CD8+ T cell responses in convalescent COVID-19

Characterization of pre-existing and induced SARS-CoV-2-specific CD8+ T cells

Sequence-based prediction of SARS-CoV-2 vaccine targets 30 using a mass spectrometry-based bioinformatics predictor identifies immunogenic T cell epitopes

SARS-CoV-2 elicits robust adaptive immune responses regardless 4 of disease severity

Robust T cell immunity in convalescent individuals with 10 asymptomatic or mild COVID-19

Unbiased screens show CD8+ T cells of COVID-19 patients recognize 13 shared epitopes in SARS-CoV-2 that largely reside outside the spike Protein

Broad and strong memory CD4+ and CD8+ T cells induced by SARS-CoV-2 in UK convalescent 16 individuals following COVID-19

PD-1-expressing SARS-CoV-2-specific CD8+ T cells are not exhausted, but functional in patients 19 with COVID-19

T-Scan: A genome-wide method for the systematic discovery of T cell epitopes

SARS-CoV-2-derived peptides define heterologous and COVID-19-induced T cell 25 recognition

Reactive CD8+ T Cell Receptors with High Functional Avidity to a SARS-CoV

Immunodominant Epitope and Its Natural Mutant Variants. bioRxiv

Structural topology defines protective CD8+ T cell epitopes 1 in the HIV proteome

Comprehensive analysis of T cell immunodominance and immunoprevalence of

SARS-CoV-2 epitopes in COVID-19 cases

Comparative analysis of activation induced marker (AIM) assays

for sensitive identification of antigen-specific CD4 T cells

NetCTLpan: Pan-specific MHC class I 9 pathway epitope predictions

Gapped sequence alignment using artificial neural networks: 11 Application to the MHC class I system

NetMHCpan, a method for quantitative predictions of peptide binding to any

NetMHCpan-4.0: Improved 16 peptide-MHC class I interaction predictions integrating eluted ligand and peptide binding affinity data

Reliable prediction of T-cell epitopes using neural networks with novel sequence representations

Mass spectrometry profiling of HLA-associated peptidomes in mono-28 allelic cells enables more accurate epitope prediction

MAFFT multiple sequence alignment software version 7: Improvements 30 in performance and usability